CAPR — CAPRICOR THERAPEUTICS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1133869 ·
Last close
$8.41
Market Cap
$488.98M
52W High
$40.37
52W Low
$2.96
ADV30
3,566,837
Next earnings
2026-11-10
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -44,682,736 | -42,656,101 | 330,370,421 | 44,279,993 | 120,605,812 |
| Jun 2026 | 0 | — | -42,945,620 | -40,733,654 | 368,735,835 | 20,935,187 | 122,516,945 |
| Mar 2026 | 0 | — | -36,772,853 | -33,941,345 | 326,283,517 | 105,421,484 | 47,580,884 |
| Dec 2025 | 0 | — | -29,156,008 | -30,170,914 | 355,949,294 | 287,847,312 | 50,157,149 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-119,994,953
Investing CF
$-100,409,531
Financing CF
$246,131,709
CapEx
$-26,291,272
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.64
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-422,209,585
Inventory
—
Receivables
$0
ST Investments
$153,300,986
EBIT TTM
$-147,411,708
Pretax Income TTM
$-147,498,814
Interest Exp TTM
—
Analysts
6
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -108,142,130 | -105,043,946 | 355,949,294 | 50,157,149 | 305,792,145 | -69,811,261 |
| Dec 2024 | 22,270,465 | -42,563,242 | -40,467,186 | 170,481,086 | 25,018,750 | 145,462,336 | -39,995,742 |
| Dec 2023 | 25,178,066 | -24,077,859 | -22,287,542 | 58,734,327 | 36,132,860 | 22,601,467 | -25,596,545 |
| Dec 2022 | 2,551,469 | -29,697,383 | -29,019,532 | 50,094,910 | 38,308,816 | 11,786,094 | 4,916,637 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-129,416,560
OpCashFlow TTM
—
Assets (Latest)
$368,735,835
Forward EPS
$-1.31
Max Pain — expiry 2026-11-27
max pain strike: $8.50 · spot: $8.03 · call oi: 5,952 · put oi: 10,197
Expected Move to 2026-11-27:
±$8.53
(106.16%) —
implied range
$-0.50 –
$16.55
· ATM straddle on $8.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| GYRE | GYRE THERAPEUTICS, INC. | $488.23M | $4.56 | — |
| MNPR | Monopar Therapeutics | $481.56M | $71.06 | — |
| BLSM | BlossomHill Therapeutics, Inc. | $480.91M | $15.13 | — |
| IMMP | IMMUTEP Ltd | $480.43M | $3.26 | — |
| NGNE | Neurogene Inc. | $478.19M | $23.10 | — |
News headlines (Yahoo Finance, 1h cache)
CAPR Stock Has Retail’s Attention After SLS Rally — Here Are 2 Drugs With Better FDA Approval Odds This Month
2026-11-18 07:51 · Yahoo
‘Pharma Bro’ Shkreli Calls SLS Results ‘Sketch,’ Compares Leukemia Vaccine Data To Capricor’s Deramiocel
2026-11-17 20:53 · Yahoo
FDA Decision Watch: Capricor’s DMD Therapy Faces Make-Or-Break Decision, Savara’s Lung Disease Drug In The Spotlight This Week
2026-11-16 10:09 · Yahoo
SMMT Stock Plunges Overnight On FDA Rejection — CAPR Holders Feel The Jitters Ahead Of Their Own FDA Test
2026-11-16 01:49 · Yahoo
CAPR Stock Rallies: Investors Scrutinize Labeling Hints Before FDA Decision On Cell Therapy This Month
2026-11-11 17:42 · Yahoo
Capricor Therapeutics, Inc. Q3 2026 Earnings Call Summary
2026-11-11 13:30 · Yahoo
Capricor Therapeutics Inc (CAPR) (Q3 2026) Earnings Call Highlights: Deramiocel Nears PDUFA ...
2026-11-11 07:08 · Yahoo
Capricor (CAPR) Q3 2026 Earnings Call Transcript
2026-11-11 03:34 · Yahoo
Capricor Therapeutics Q3 Earnings Call Highlights
2026-11-11 00:14 · Yahoo
CAPR Stock Rallies After-Hours As Capricor Reaffirms Deramiocel Confidence Ahead Of Nov. 22 Decision; Says Application In Final Review
2026-11-10 23:56 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.